The proportion of CD11c+CD40+ tumor‐infiltrating DCs in PNVAC+ISA 51 group was 1.60‐fold higher than that in free vaccine‐treated group (Figure S6c, Supporting Information, free vaccine+ISA 51 vs PNVAC+ISA 51: 42.87 vs 68.67, P < 0.001). This evidence concerns the gene ITGAX and neoplasm.